FDG-PET/CT alters treatment in node-positive penile cancer

NoDe-pOsitive penile cancer and FDG-PET/CT – does PET modify treatment? (DO PET)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN49141161

Enrollment

100

Registered

2023-06-29

Start date

2020-02-27

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Penile cancer Cancer

Interventions

The researchers prospectively apply FDG-PET/CT in all penile cancer patients with node-positive disease to investigate the proportion of patients subjected to altered treatment based on the FDG-PET/CT

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Node-positive penile cancer (cN+ or cN3 after sentinel node biopsy)

Exclusion criteria

Exclusion criteria: Age below 18 years

Design outcomes

Primary

Measure	Time frame
Altered treatment according to FDG-PET/CT findings, measured using FDG-PET/CT discussions at multidisciplinary team (MDT) prior to planning definitive treatment	—

Secondary

Measure	Time frame
Sensitivity for detection of iliac lymph node metastases, measured using FDG-PET/CT discussions at multidisciplinary team (MDT) prior to planning definitive treatment	—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026